Pipeline
Therapies that Target the INNATE IMMUNE Response
| DN-TNF Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal | EST. NEXT MILESTONE |
|---|---|---|---|---|---|---|
XPRO™ |
Early Alzheimer’s | P2 Data 2024 | ||||
XPRO™ |
Treatment Resistant Depression |
P2 Start 1H 2024 | ||||
| pSar DN-TNF | DMD Cancer Other |
Future Development and/or Partnership |
| NK-Priming Platform | Disease Field | Pre-clinical | Phase I | Phase II (POC) | Pivotal | EST. NEXT MILESTONE |
|---|---|---|---|---|---|---|
INKmune™ |
Myelodysplastic Syndrome ONCOLOGY |
P1 Data 2023 | ||||
INKmune™ |
Metastatic CastrationResistant Prostate Cancer | P1/2 Start 2H 2023 |
INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic